| Qian, Wenbin |
NCT06134284: Clinical Study of OR for Second-line Treatment of Refractory MZL |
|
|
| Recruiting | 4 | 39 | RoW | Orelabrutinib combined with rituximab | Lixia Sheng | OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma | 12/26 | 12/29 | | |
NCT04910594: Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | recombinant human erythropoietin, EPO | Second Affiliated Hospital, School of Medicine, Zhejiang University, First People's Hospital of Hangzhou, Zhejiang Provincial Tongde Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Cancer Hospital, Wenzhou Central Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Jiaxing University, Taizhou Hospital of Zhejiang Province, Second Affiliated Hospital of Wenzhou Medical University | Lymphoma, Anemia | 02/23 | 04/23 | | |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06508983: A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 360 | RoW | SG301 Injection, SG301 placebo, pomalidomide, dexamethasone | Hangzhou Sumgen Biotech Co., Ltd. | Relapsed/Refractory Multiple Myeloma | 03/27 | 03/28 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
NCT03931421: B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma |
|
|
| Recruiting | 2 | 30 | RoW | CAR-T treatment | First Affiliated Hospital of Zhejiang University | Multiple Myeloma | 11/22 | 12/22 | | |
NCT04659434: Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL |
|
|
| Not yet recruiting | 2 | 51 | RoW | Sintilimab, IBI308 | Qian Wenbin | Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 12/22 | 12/25 | | |
NCT06290817: Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI |
|
|
| Recruiting | 2 | 62 | RoW | Orelabrutinib combined with R-CDOP regimen | Second Affiliated Hospital, School of Medicine, Zhejiang University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Huizhou Municipal Central Hospital, Ningbo Medical Center Lihuili Hospital, Affiliated Hospital of Jiaxing University, The Second Affiliated Hospital of Jiaxing University | Diffuse Large B-cell Lymphoma | 03/25 | 03/26 | | |
NCT03934567: A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma |
|
|
| Recruiting | 2 | 96 | RoW | Abexinostat | Xynomic Pharmaceuticals, Inc. | Lymphoma, Follicular | 02/24 | 09/24 | | |
NCT05495100: A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 45 | RoW | Mitoxantrone liposome、Chidamide、Azacitidine | Second Affiliated Hospital, School of Medicine, Zhejiang University, Ningbo No. 1 Hospital, Jinhua Central Hospital, Huizhou Municipal Central Hospital | Peripheral T Cell Lymphoma | 08/23 | 08/24 | | |
NCT06554600: A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2 | 36 | RoW | Zanubrutinib, Polatuzumab Vedotin, Bendamustine, Rituximab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Refractory or Relapsed Diffuse Large B Cell Lymphoma | 08/26 | 08/28 | | |
NCT06092606: A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients |
|
|
| Recruiting | 2 | 90 | RoW | Control group:DH001 placebo, Control group, Trial group: DH001 low-dose group, Trial group: DH001 high-dose group | Monyan Pharmaceutical (Shanghai) Co., Ltd. | Cancer, Heart Failure, Arrhythmia, Doxorubicin Induced Cardiomyopathy, Doxorubicin Adverse Reaction | 01/25 | 01/25 | | |
NCT05600660: Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma |
|
|
| Recruiting | 2 | 28 | RoW | Orelabrutinib, Rituximab, Methotrexate | Second Affiliated Hospital, School of Medicine, Zhejiang University | Primary Central Nervous System Lymphoma | 12/25 | 12/27 | | |
NCT04202003: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
|
|
| Completed | 1/2 | 105 | RoW | TJ011133 | TJ Biopharma Co., Ltd. | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | 12/23 | 12/23 | | |
|
|
NCT04674514: APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 48 | RoW | APG-2575, Rd, Lenalidomide +Dexamethasone | Ascentage Pharma Group Inc. | Multiple Myeloma | 01/24 | 05/24 | | |
GFH009X2101, NCT04588922: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies |
|
|
| Recruiting | 1/2 | 160 | US, RoW | SLS009, GFH009, venetoclax, Venclexta, azacitidine, Vidaza, azacytidine | Sellas Life Sciences Group, Sellas Life Sciences Group | Hematologic Malignancies | 06/25 | 12/25 | | |
| Recruiting | 1/2 | 120 | RoW | Chidamide, HDACi, Fludarabine and cyclophosphamide, FC regimen, Anti-CD19 CAR-T cells, Relma-cel, Axi-cel, Other commercial CAR-T cells, Experimental CAR-T cells | Chinese PLA General Hospital | Non Hodgkin's Lymphoma | 06/24 | 06/25 | | |
NCT06556199: A Study of Selinexor in Combination With Temozolomide and Anti-PD-1 Antibody in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma |
|
|
| Recruiting | 1/2 | 38 | RoW | Selinexor, Temozolomide, Anti-PD-1 monoclonal antibody | Second Affiliated Hospital, School of Medicine, Zhejiang University | Relapsed/Refractory Primary Central Nervous System Lymphoma | 08/26 | 08/28 | | |
NCT06554561: A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System Lymphoma |
|
|
| Recruiting | 1/2 | 43 | RoW | Pomalidomide, Rituximab, Methotrexate | Second Affiliated Hospital, School of Medicine, Zhejiang University | PCNSL | 08/26 | 08/29 | | |
NCT04494503: Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL |
|
|
| Recruiting | 1/2 | 123 | RoW | APG-2575, Rituximab, Ibrutinib | Ascentage Pharma Group Inc. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 12/25 | | |
NCT04887012: Clinical Study of HLA Haploidentical CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL |
|
|
| Recruiting | 1 | 25 | RoW | anti-CD19 CAR-NK, CAR-NK019 | Second Affiliated Hospital, School of Medicine, Zhejiang University | B-cell Non Hodgkin Lymphoma | 05/22 | 05/24 | | |
NCT04887025: Exploratory Study of a Novel Oncolytic Vaccinia Virus RGV004 in the Treatment of Refractory/Relapsed B-cell Lymphoma |
|
|
| Recruiting | 1 | 25 | RoW | RGV004 | Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou Rongu Biotechnology Co., Ltd. | Relapsed or Refractory B-cell Lymphoma | 03/23 | 03/25 | | |
NCT04861779: A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies |
|
|
| Recruiting | 1 | 156 | RoW | HSK29116 | Haisco Pharmaceutical Group Co., Ltd. | Relapsed/Refractory B-Cell Malignancies | 08/23 | 10/23 | | |
CICPD, NCT04381741: CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Enrolling by invitation | 1 | 24 | RoW | CD19-7×19 CAR-T plus PD1 monoclonal antibody | Second Affiliated Hospital, School of Medicine, Zhejiang University | Diffuse Large B-cell Lymphoma | 09/23 | 09/23 | | |
NCT05472558: Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL |
|
|
| Recruiting | 1 | 48 | RoW | anti-CD19 CAR-NK, CB CAR-NK019 | Second Affiliated Hospital, School of Medicine, Zhejiang University | B-cell Non Hodgkin Lymphoma | 09/23 | 09/25 | | |
NCT04706936: Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma |
|
|
| Recruiting | 1 | 25 | RoW | anti-BCMA CAR-T, CBG-002 CAR-T, Cyclophosphamid, Fludarabine | Second Affiliated Hospital, School of Medicine, Zhejiang University, Carbiogene Therapeutics Co. Ltd. | Relapsed or Refractory Multiple Myeloma | 10/23 | 04/24 | | |
NCT04795128: A Study Evaluating the Safety, Tolerability and Preliminary Efficacy of IBI322 in Subjects With Hematologic Malignancy |
|
|
| Completed | 1 | 70 | RoW | IBI322 | Innovent Biologics (Suzhou) Co. Ltd. | Hematologic Malignancy | 08/23 | 08/23 | | |
IR2022000371, NCT05453669: Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL |
|
|
| Recruiting | 1 | 12 | RoW | CD19-CAR-DNT cells | Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Ruijiamei Biotechnologies, Co., Ltd. | B-cell Non-Hodgkin's Lymphoma | 06/24 | 06/25 | | |
NCT05659628: CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL |
|
|
| Recruiting | 1 | 24 | RoW | CD19-7×19 CAR-T combined with Tislelizumab | Ningbo No. 1 Hospital, Zhejiang University | Diffuse Large B-cell Lymphoma | 12/24 | 12/26 | | |
NCT05667155: Clinical Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma |
|
|
| Recruiting | 1 | 48 | RoW | CB dualCAR-NK19/70 | Second Affiliated Hospital, School of Medicine, Zhejiang University | B-cell Non Hodgkin Lymphoma | 01/25 | 12/25 | | |
NCT05585996: Exploratory Clinical Study of CD19-targeted CAR-T and CAR-DC in the Treatment of Relapsed and Refractory B-cell Lymphoma |
|
|
| Recruiting | 1 | 70 | RoW | CD19 CAR-T and CD19 CAR-DC | Second Affiliated Hospital, School of Medicine, Zhejiang University | Relapsed and Refractory B-cell Lymphoma | 11/25 | 12/25 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 01/25 | 01/25 | | |
| Xiao, Xibin |
NCT04910594: Clinical Study the Efficacy and Safety of Rh-EPO in the Treatment of Anemia in Lymphoma |
|
|
| Recruiting | 3 | 130 | RoW | recombinant human erythropoietin, EPO | Second Affiliated Hospital, School of Medicine, Zhejiang University, First People's Hospital of Hangzhou, Zhejiang Provincial Tongde Hospital, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Cancer Hospital, Wenzhou Central Hospital, First Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, First Affiliated Hospital of Jiaxing University, Taizhou Hospital of Zhejiang Province, Second Affiliated Hospital of Wenzhou Medical University | Lymphoma, Anemia | 02/23 | 04/23 | | |
NCT06290817: Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI |
|
|
| Recruiting | 2 | 62 | RoW | Orelabrutinib combined with R-CDOP regimen | Second Affiliated Hospital, School of Medicine, Zhejiang University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Huizhou Municipal Central Hospital, Ningbo Medical Center Lihuili Hospital, Affiliated Hospital of Jiaxing University, The Second Affiliated Hospital of Jiaxing University | Diffuse Large B-cell Lymphoma | 03/25 | 03/26 | | |
NCT05495100: A Single-arm, Multicenter, Prospective Clinical Study of Mitoxantrone Liposome Combined With Chidamide and Azacitidine in the Treatment of Relapsed and Refractory Peripheral T-cell Lymphoma |
|
|
| Recruiting | 2 | 45 | RoW | Mitoxantrone liposome、Chidamide、Azacitidine | Second Affiliated Hospital, School of Medicine, Zhejiang University, Ningbo No. 1 Hospital, Jinhua Central Hospital, Huizhou Municipal Central Hospital | Peripheral T Cell Lymphoma | 08/23 | 08/24 | | |
| Ye, Panpan |
NCT06572553: Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients |
|
|
| Recruiting | 2/3 | 30 | RoW | Faricimab | Second Affiliated Hospital, School of Medicine, Zhejiang University | Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion | 08/24 | 08/24 | | |
NCT06527326: the Study of the Association Between the Gut Microbiota and Central Serous Chorioretinopathy |
|
|
| Recruiting | N/A | 400 | RoW | Live Combined Bifidobacterium, Placebo | Second Affiliated Hospital, School of Medicine, Zhejiang University | Central Serous Chorioretinopathy | 07/25 | 07/26 | | |
